Fusion protein and use thereof in gene editing

By fusing T5 exonuclease with Cas12i3 protein to form a fusion protein, the problem of low editing efficiency of Cas12i3 protein is solved, the gene editing efficiency is significantly improved, and it has good application value.

WO2024230183A1PCT designated stage expired Publication Date: 2024-11-14CHINA AGRI UNIV

Patent Information

Application Number
PCT/CN2023/140817
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2023-12-22
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The low editing efficiency of Cas12i3 protein in gene editing has led to limited application in areas such as gene editing, gene function research and animal and plant genetic improvement.

Method used

By designing combinations of different linkers and Cas12i3 proteins, such as C-linker 3 combination, N-linker 4 combination and C-linker 1 combination, T5 exonuclease is fused with Cas12i3 protein to form a fusion protein to improve editing efficiency.

Benefits of technology

The gene editing efficiency of Cas12i3 protein was significantly improved, specifically improved by 35.9% to 32.5%. The detection by flow analysis method was used to enhance the quenching ratio of tdTomato fluorescence intensity and the proportion of weak fluorescent cells. The overall fluorescence peak map was translated to the left. , indicating that the editing efficiency is improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2023140817-FTAPPB-I100001
    Figure PCTCN2023140817-FTAPPB-I100001
  • Figure PCTCN2023140817-FTAPPB-I100002
    Figure PCTCN2023140817-FTAPPB-I100002
  • Figure PCTCN2023140817-FTAPPB-I100003
    Figure PCTCN2023140817-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are a fusion protein and use thereof in gene editing. Specifically, disclosed is a fusion protein for improving gene editing efficiency, and the fusion protein is a protein having an amino acid sequence of SEQ ID No. 9, SEQ ID No. 11, or SEQ ID No. 13. Also provided are a gene editing system and a method for improving Cas12i3 protein-mediated gene editing efficiency. A coding sequence nucleic acid molecule combination of T5 exonuclease and a linker capable of significantly improving the Cas enzyme editing efficiency is acquired by means of screening. Compared with an unmodified Cas12i3 protein, the fusion protein acquired by the combination exhibits significantly improved editing efficiency. Further flow cytometry analysis results show that by means of modification with the C-linker 3 combination, the editing efficiency of the Cas enzyme is further significantly improved. The provided gene editing system features high editing efficiency and possesses high application values and broad prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Fusion proteins and their applications in gene editing Technical Field

[0001] The present invention belongs to the field of gene editing engineering, relates to fusion proteins and their applications in gene editing, and specifically to a nucleic acid molecule combination encoding T5 exonuclease and linker and their applications. Background Art

[0002] Exonucleases are enzymes that sequentially hydrolyze 3', 5'-phosphodiester bonds from one end of a polynucleotide chain, degrading nucleotides. T5 exonuclease (T5 exo), derived from the bacteriophage T5, degrades double-stranded or single-stranded DNA in a 5' to 3' direction.

[0003] CRISPR / Cas is an adaptive immune system produced by prokaryotes to resist viral infection or phage invasion. Among them, the type II CRISPR / Cas9 system and the type V system (such as CRISPR / Cas12a, CRISPR / Cas12b, etc.) are simple in composition, easy to operate, and are widely used in gene editing. After the CRISPR / Cas9 system recognizes the DNA target through a single guide RNA (sgRNA), Cas9 usually produces a double-strand break. The cell then repairs the double-strand break through the non-homologous end joining mechanism and the homologous recombination repair mechanism, thereby producing insertions, deletions, or gene insertions and specific base changes when there is a donor template. At present, CRISPR / Cas9 technology has been widely used in many species such as microorganisms, animals and plants. The CRISPR / Cas system has broken the limitations of traditional breeding and accelerated the process of genetic improvement of animals and plants.

[0004] Chinese invention patent CN111757889B discloses a Cas protein Cas12f.4, which is referred to as Cas12i3 in this article. This Cas protein can be edited in eukaryotes. The cleavage site of the Cas12i3 protein is located 15nt and 22nt downstream of the PAM, and after cutting, a 7nt 5' overhang is generated. The overhang is complementary and paired, resulting in a bias towards accurate repair of breaks during cell repair, reducing editing efficiency. Therefore, it is necessary to further improve the CRISPR / Cas12i3 gene editing system, improve its editing efficiency, and develop a more efficient gene editing system so that it has a wider range of application value in the fields of gene editing, gene function research, and genetic improvement of plants and animals.

[0005] SUMMARY OF THE INVENTION

[0006] The technical problem to be solved by the present invention is how to improve the efficiency of gene editing mediated by Cas12i3 protein. The technical problem to be solved is not limited to the described technical subject matter, and those skilled in the art can clearly understand other technical subjects not mentioned herein through the following description.

[0007] To solve the above technical problems, the present invention first provides a fusion protein that improves gene editing efficiency. The fusion protein can be any of the following:

[0008] A1) a protein having an amino acid sequence of SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13;

[0009] A2) a protein having at least 80% identity with the protein of A1) and having the same function as the protein of A1) obtained by substitution and / or deletion and / or addition of amino acid residues of the amino acid sequence of SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13;

[0010] A3) A fusion protein having the same function obtained by connecting a tag or signal peptide to the N-terminus and / or C-terminus of A1) or A2).

[0011] The connection in A3) is achieved via a peptide bond.

[0012] The substitutions described herein can be conservative substitutions (also known as conservative replacements) or non-conservative substitutions in non-core functional regions. It is well known to those skilled in the art that conservative substitutions or non-conservative substitutions in non-core functional regions generally do not have a qualitative effect on the function of the protein.

[0013] The tags described herein include, but are not limited to, GST (glutathione sulfhydryltransferase) tag protein, His-tag protein (His-tag), MBP (maltose binding protein) tag protein, Flag tag protein, SUMO tag protein, HA tag protein, Myc tag protein, eGFP (enhanced green fluorescent protein), eCFP (enhanced cyan fluorescent protein), eYFP (enhanced yellow-green fluorescent protein), mCherry (monomeric red fluorescent protein) or AviTag tag protein.

[0014] As used herein, identity refers to the identity of an amino acid sequence or a nucleotide sequence. The identity of an amino acid sequence can be determined using a homology search site on the Internet, such as the BLAST page on the NCBI homepage. For example, in Advanced BLAST 2.1, by using blastp as the program, setting the Expect value to 10, all filters to OFF, using BLOSUM62 as the matrix, and setting the Gap existence cost, Per residue gap cost, and Lambda ratio to 11, 1, and 0.85 (default values), respectively, and performing a search to calculate the identity of the amino acid sequence, the value (%) of identity can then be obtained.

[0015] Herein, the greater than 80% identity may be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity.

[0016] The present invention also provides a nucleic acid molecule, which may be any of the following:

[0017] B1) a nucleic acid molecule encoding any one of the fusion proteins described herein;

[0018] B2) the coding sequence is a DNA molecule represented by SEQ ID No. 10, SEQ ID No. 12 or SEQ ID No. 14;

[0019] B3) The nucleotide sequence is a DNA molecule shown by SEQ ID No. 10, SEQ ID No. 12 or SEQ ID No. 14.

[0020] The nucleic acid molecule may also include a nucleic acid molecule obtained by modifying the codon preference based on the nucleotide sequence shown in SEQ ID No. 10, SEQ ID No. 12, or SEQ ID No. 14. Considering the degeneracy of codons and the codon preferences of different species, those skilled in the art can use codons suitable for expression in a specific species as needed.

[0021] The present invention also provides an expression cassette comprising a nucleic acid molecule described herein.

[0022] The present invention also provides a recombinant vector comprising the nucleic acid molecule described herein.

[0023] The present invention also provides a recombinant microorganism comprising a nucleic acid molecule as described herein.

[0024] The present invention also provides recombinant host cells containing the nucleic acid molecules described herein.

[0025] Furthermore, the expression cassette, the recombinant vector, the recombinant microorganism and the recombinant host cell can all express the nucleic acid molecule.

[0026] The microorganisms described herein may be bacteria, fungi, actinomycetes, protozoa, algae or viruses. Among them, the bacteria may be from Escherichia sp., Erwinia sp., Agrobacterium sp., Flavobacterium sp., etc., but are not limited thereto. The fungi may be yeast, and the yeast may be from Saccharomyces, Kluyveromyces, Pichia sp., etc., but are not limited thereto. The actinomycetes may be from Streptomyces sp., Nocardia sp., Micromonospora sp., etc., but are not limited thereto. The algae may be from Fucus sp., Achnanthes sp., etc., but are not limited thereto. The virus may be rotavirus, herpes virus, influenza virus, adenovirus, etc., but are not limited thereto.

[0027] The host cells (also referred to as recipient cells) described herein can be plant cells or animal cells. The host cells can be understood to refer not only to specific recipient cells, but also to the progeny of such cells, and due to natural, accidental or intentional mutations and / or changes, the progeny may not necessarily be completely identical to the original parent cell, but are still included in the scope of host cells. Suitable host cells are known in the art, wherein: the plant cells may be, but are not limited to, plant cells such as Arabidopsis thaliana, tobacco (Nicotiana tabacum), corn (Zea mays), rice (Oryza sativa), and wheat (Triticum aestivum); the animal cells may be, but are not limited to, mammalian cells (e.g., Chinese hamster ovary cells (CHO cells), African green monkey kidney cells (Vero cells), baby hamster kidney cells (BHK cells), mouse breast cancer cells (C127 cells), human embryonic kidney cells (HEK293 cells), human HeLa cells, fibroblasts, bone marrow cell lines, T cells, or NK cells), avian cells (e.g., chicken or duck cells), amphibian cells (e.g., African clawed frog (Xenopus laevis) cells or giant salamander (Andrias davidianus) cells), fish cells (e.g., grass carp, carp, rainbow trout, or catfish cells), insect cells (e.g., Sf21 cells or Sf-9 cells), etc. In one or more embodiments of the present invention, the host cell is an ovine fibroblast.

[0028] The present invention also provides any of the following applications of the fusion protein:

[0029] D1) Application in gene editing;

[0030] D2) Application in the preparation of gene editing systems;

[0031] D3) Application in the preparation of gene editing products;

[0032] D4) Application in improving gene editing efficiency.

[0033] The present invention also provides any of the following uses of the nucleic acid molecule:

[0034] D1) Application in gene editing;

[0035] D2) Application in the preparation of gene editing systems;

[0036] D3) Application in the preparation of gene editing products;

[0037] D4) Application in improving gene editing efficiency.

[0038] The present invention also provides any of the following applications of the expression cassette:

[0039] D1) Application in gene editing;

[0040] D2) Application in the preparation of gene editing systems;

[0041] D3) Application in the preparation of gene editing products;

[0042] D4) Application in improving gene editing efficiency.

[0043] The present invention also provides any of the following applications of the recombinant vector:

[0044] D1) Application in gene editing;

[0045] D2) Application in the preparation of gene editing systems;

[0046] D3) Application in the preparation of gene editing products;

[0047] D4) Application in improving gene editing efficiency.

[0048] The present invention also provides any of the following uses of the recombinant microorganism:

[0049] D1) Application in gene editing;

[0050] D2) Application in the preparation of gene editing systems;

[0051] D3) Application in the preparation of gene editing products;

[0052] D4) Application in improving gene editing efficiency.

[0053] The present invention also provides any of the following uses of the recombinant host cell:

[0054] D1) Application in gene editing;

[0055] D2) Application in the preparation of gene editing systems;

[0056] D3) Application in the preparation of gene editing products;

[0057] D4) Application in improving gene editing efficiency.

[0058] The gene editing described herein may be gene editing of eukaryotes or prokaryotes, or gene editing of eukaryotic cells or prokaryotic cells. The eukaryotic organisms may include animals or plants;

[0059] The gene editing products described herein may include, but are not limited to, cell models, animal or plant models, new animal or plant varieties, etc.

[0060] The present invention also provides a gene editing system (composition), which may include at least any one of the following:

[0061] E1) the fusion protein;

[0062] E2) the nucleic acid molecule;

[0063] E3) the recombinant vector.

[0064] Furthermore, the gene editing system may also include gRNA (guide RNA) or a gRNA expression vector.

[0065] The gRNA expression vector may be a recombinant vector containing a DNA molecule encoding the gRNA.

[0066] The gRNA guides the fusion protein to perform gene editing on the target gene in the target cell.

[0067] The gene editing system described herein may be a Cas12i3 protein-mediated gene editing system (CRISPR / Cas12i3 gene editing system).

[0068] The present invention also provides the use of the gene editing system in gene editing, preparing gene editing products or improving gene editing efficiency.

[0069] The present invention also provides a method for gene editing, which may include the step of performing gene editing using the fusion protein, the nucleic acid molecule, the recombinant vector and / or the gene editing system.

[0070] Furthermore, the gene editing method may include: contacting the sample to be edited with the fusion protein, the nucleic acid molecule, the recombinant vector and / or the gene editing system to perform gene editing.

[0071] The sample to be edited may include cells (such as animal cells or plant cells), tissues, organs, or a combination thereof.

[0072] The sample may be from an animal, a plant or a microorganism (including bacteria, viruses, etc.).

[0073] The gene editing described herein includes in vitro gene editing, in vivo gene editing, or a combination thereof.

[0074] The gene editing described herein may include gene knockout, gene knockin, gene mutation, gene fragment replacement or gene modification.

[0075] The present invention also provides a method for improving the efficiency of Cas protein-mediated gene editing, which may include any of the following:

[0076] F1) connecting T5 exonuclease to the C-terminus of the Cas protein via linker 3, wherein the linker 3 is a polypeptide with an amino acid sequence of SEQ ID No. 3;

[0077] F2) connecting T5 exonuclease to the N-terminus of the Cas protein via linker 4, wherein the linker 4 is a polypeptide having an amino acid sequence of SEQ ID No. 4;

[0078] F3) T5 exonuclease is connected to the C-terminus of the Cas protein through linker 1, and the linker 1 is a polypeptide with an amino acid sequence of SEQ ID No. 1.

[0079] In the above method, the connection is achieved through a peptide bond.

[0080] Furthermore, the Cas protein may include Cas12i3, Cas9, Cas12a, Cas12b, Cas13a, and Cas14 proteins but is not limited thereto.

[0081] Furthermore, the Cas protein may be a Cas12 family protein.

[0082] Furthermore, the Cas protein may be Cas12i3 protein.

[0083] Furthermore, the method may also include the step of constructing the nucleic acid molecule (a nucleic acid molecule encoding any of the fusion proteins described herein) and the nucleic acid molecule encoding gRNA into a vector to prepare a gene editing vector.

[0084] The fusion protein described herein may include Cas12i3 protein, T5 nuclease and a linker.

[0085] The amino acid sequence of the Cas12i3 protein may be positions 1-1045 of SEQ ID No. 9, and the nucleotide sequence of the gene encoding the Cas12i3 protein may be positions 1-3135 of SEQ ID No. 10.

[0086] The amino acid sequence of T5 exonuclease may be positions 1056-1346 of SEQ ID No. 9, and the nucleotide sequence of the gene encoding T5 exonuclease may be positions 3166-4038 of SEQ ID No. 10.

[0087] The linker peptide may be linker 1 (the amino acid sequence may be SEQ ID No. 1), linker 3 (the amino acid sequence may be SEQ ID No. 3), or linker 4 (the amino acid sequence may be SEQ ID No. 4).

[0088] The combined connection modes of the Cas12i3 protein, T5 exonuclease and connecting peptide (linker) include: C-linker 3 combination mode, N-linker 4 combination mode and C-linker 1 combination mode. The C-linker 3 combination mode is to connect T5 exonuclease to the C-terminus of the Cas12i3 protein through linker 3; the N-linker 4 combination mode is to connect T5 exonuclease to the N-terminus of the Cas12i3 protein through linker 4; the C-linker 1 combination mode is to connect T5 exonuclease to the C-terminus of the Cas12i3 protein through linker 1.

[0089] In one embodiment of the present invention, the fusion protein obtained after transforming the Cas12i3 protein in a C-linker 3 combination manner is Cas12i3-SGGSGGSGGS-T5 exo. The amino acid sequence of the fusion protein Cas12i3-SGGSGG SGGS-T5 exo is SEQ ID No.9, the encoding gene is the Cas12i3-linker 3-T5 exo gene, and the nucleotide sequence of the Cas12i3-linker 3-T5 exo gene is SEQ ID No.10.

[0090] In one embodiment of the present invention, the fusion protein obtained after transforming the Cas12i3 protein in accordance with the N-linker 4 combination is T5 exo-XTEN-Cas12i3. The amino acid sequence of the fusion protein T5 exo-XTEN-Cas12i3 is SEQ ID No. 11, the encoding gene thereof is the T5 exo-linker 4-Cas12i3 gene, and the nucleotide sequence of the T5 exo-linker 4-Cas12i3 gene is SEQ ID No. 12.

[0091] In one embodiment of the present invention, the fusion protein obtained after transforming the Cas12i3 protein in a C-linker 1 combination manner is Cas12i3-(GGGGS)2-T5 exo. The amino acid sequence of the fusion protein Cas12i3-(GGGGS)2-T5 exo is SEQ ID No.13, the encoding gene is the Cas12i3-linker 1-T5 exo gene, and the nucleotide sequence of the Cas12i3-linker 1-T5 exo gene is SEQ ID No.14.

[0092] The gene editing system described herein may include a gene editing vector, which may be a recombinant vector obtained by constructing any of the nucleic acid molecules described herein and a nucleic acid molecule encoding a gRNA into a vector.

[0093] In one embodiment of the present invention, the gRNA is a gRNA targeting the sheep endogenous gene ZFX, and the target sequence of the gRNA is SEQ ID No. 15. The gene editing vector includes: a recombinant vector obtained by constructing the DNA molecule shown in SEQ ID No. 15 and the Cas12i3-linker 3-T5 exo gene (SEQ ID No. 10) into a vector, a recombinant vector obtained by constructing the DNA molecule shown in SEQ ID No. 15 and the T5 exo-linker 4-Cas12i3 gene (SEQ ID No. 12) into a vector, and a recombinant vector obtained by constructing the DNA molecule shown in SEQ ID No. 15 and the Cas12i3-linker 1-T5 exo gene (SEQ ID No. 14) into a vector.

[0094] The above-mentioned gene editing vector contains the ZFX gene editing target and the fusion gene designed by the present invention (including the coding gene of the Cas12i3 protein, the coding gene of the T5 nuclease, and the linker gene designed by the present invention). After being introduced into the recipient cell, the guide RNA transcribed therefrom can target the ZFX gene through base complementary pairing, and the fusion protein expressed therefrom (a fusion protein formed by connecting the Cas12i3 protein and the T5 nuclease through a linker) causes double-strand breaks in the DNA upstream and downstream of the ZFX gene target, and further realizes the gene editing function through the organism's own DNA damage repair response mechanism.

[0095] In another embodiment of the present invention, the gRNA is a gRNA targeting the tdTomato gene, and the target sequence of the gRNA is SEQ ID No. 16. The gene editing vector includes: a recombinant vector obtained by constructing the DNA molecule shown in SEQ ID No. 16 and the Cas12i3-linker 3-T5 exo gene (SEQ ID No. 10) into a vector, a recombinant vector obtained by constructing the DNA molecule shown in SEQ ID No. 16 and the T5 exo-linker4-Cas12i3 gene (SEQ ID No. 12) into a vector, and a recombinant vector obtained by constructing the DNA molecule shown in SEQ ID No. 16 and the Cas12i3-linker 1-T5 exo gene (SEQ ID No. 14) into a vector.

[0096] The above-mentioned gene editing vector contains the tdTomato gene editing target and the fusion gene designed by the present invention (including the coding gene of the Cas12i3 protein, the coding gene of the T5 nuclease, and the linker gene designed by the present invention). After being introduced into the recipient cell, the guide RNA transcribed therefrom can target the tdTomato gene through base complementary pairing, and the fusion protein expressed therefrom (a fusion protein formed by connecting the Cas12i3 protein and the T5 nuclease through a linker) causes double-strand breaks in the DNA upstream and downstream of the tdTomato gene target, and further realizes the gene editing function through the organism's own DNA damage repair response mechanism.

[0097] Chinese invention patent CN111757889B discloses a Cas protein Cas12f.4, which is referred to as Cas12i3 in this article. The Cas protein can be edited in eukaryotes. The Cas12i3 protein cleavage site is located at 15nt and 22nt downstream of the PAM, and a 7nt 5' overhang is generated after cleavage. The overhangs are complementary and paired, resulting in a bias towards accurate repair of breaks during cell repair, reducing editing efficiency. The present invention fuses T5 exonuclease with Cas12i3 protein by designing different linkers to remove the 5' overhang, thereby improving the editing efficiency of Cas12i3 and laying the foundation for the widespread application of the CRISPR / Cas12i3 gene editing system.

[0098] The present invention obtains a combination of T5 nuclease and linker coding sequence nucleic acid molecules (C-linker 3 combination, N-linker 4 combination and C-linker 1 combination) that can significantly improve the editing efficiency of Cas enzyme by screening. The fusion protein obtained by the combination of C-linker 3 combination, N-linker 4 combination and C-linker 1 combination has a greater improvement in editing efficiency than the unmodified Cas12i3 protein, which is increased by 35.9%, 32.5% and 35.9% respectively. The results of further flow cytometry detection of the editing efficiency of different combinations showed that after the C-linker3 combination modification, the tdTomato average fluorescence intensity quenching ratio was improved, and the weak tdTomato fluorescence intensity (<10 3 ) in the tdTomato fluorescence peak, the overall tdTomato fluorescence peak shifted to the left (the coordinate axis represents the tdTomato fluorescence intensity from weak to strong from left to right), indicating that the C-linker 3 combination modification significantly improved the editing efficiency of the Cas enzyme. The gene editing system prepared using the fusion protein of the present invention has good gene editing efficiency and good application value and prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0099] Figure 1 shows the editing efficiency of eight different nucleic acid molecule combinations detected by T7E1 in sheep fibroblasts (48 h after transfection).

[0100] FIG2 is a flow cytometric analysis showing the ratio of tdTomato mean fluorescence intensity quenching in tdTomato-labeled sheep fibroblasts caused by eight different nucleic acid molecule combinations (48 h after transfection).

[0101] Figure 3 shows the weak tdTomato fluorescence intensity (<10 3 ) of the cells (48 h after transfection).

[0102] Figure 4 is a peak graph of tdTomato fluorescence distribution of tdTomato-labeled sheep fibroblasts after transfection of a control plasmid and a plasmid in which T5 exonuclease was fused to the C-terminus of Cas12i3 via linker 3 (C-linker 3 combination) (48 h after transfection). Modes for Carrying Out the Invention

[0103] The present invention will be further described in detail below in conjunction with specific embodiments. The examples provided are only for illustrating the present invention and are not intended to limit the scope of the present invention. The examples provided below can serve as a guide for further improvements by those skilled in the art and are not intended to limit the present invention in any way.

[0104] Unless otherwise specified, the experimental methods in the following examples are conventional methods and were performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials and reagents used in the following examples, unless otherwise specified, were all commercially available.

[0105] definition

[0106] While the following terms are believed to be understood by those skilled in the art, the following definitions are set forth to facilitate explanation of the subject matter disclosed herein.

[0107] gRNA

[0108] "Guide RNA" and "mature crRNA" are used interchangeably and have meanings generally understood by those skilled in the art. In general, a guide RNA may comprise a direct repeat sequence and a guide sequence, or may consist essentially of a direct repeat sequence and a guide sequence (also referred to as a spacer in the context of an endogenous CRISPR system). In some cases, a guide sequence is any polynucleotide sequence that has sufficient complementarity with a target sequence to hybridize with the target sequence and guide the specific binding of the CRISPR / Cas complex to the target sequence.

[0109] Cas proteins

[0110] In the present invention, the expression "Cas protein" refers to CRISPR protein, and the terms "CRISPR / Cas protein", "Cas effector protein", "Cas protein", and "single effector nuclease" are used interchangeably. Once the Cas protein and gRNA or mature crRNA bind to the characteristic sequence to be detected (target sequence), a ribonucleoprotein complex is formed, which contains a guide sequence that hybridizes to the target sequence and binds to the Cas protein. The ribonucleoprotein complex is capable of recognizing and cleaving a polynucleotide that can hybridize with the guide RNA or mature crRNA.

[0111] T5 exonuclease

[0112] T5 exonuclease is an enzyme that sequentially catalyzes the hydrolysis of 3,5-phosphodiester bonds from one end of a polynucleotide chain, degrading nucleotides. Derived from the bacteriophage T5, T5 exonuclease degrades double-stranded or single-stranded DNA in a 5' to 3' direction.

[0113] Fusion protein

[0114] Fusion proteins are proteins expressed by linking two proteins or polypeptides with a peptide bond. The concept of fusion proteins has important applications in cell biology research and macromolecular drug discovery. The principle of constructing a fusion protein is to delete the stop codon of the first protein gene and then attach a second protein gene with a stop codon to achieve fusion expression of the two genes. Common fusion proteins include target protein fusion tag protein, fusion fluorescent protein, and the fusion of two different proteins.

[0115] linker

[0116] Also translated as "connector peptides" or "linkers," linkers are essential components of fusion protein recombinant engineering and play a crucial role in constructing stable, biologically active fusion proteins. Linkers are amino acid chains that connect two fusion proteins, possessing a degree of flexibility to allow the proteins on either side to perform their respective functions. Direct fusion of functional domains without a linker can lead to numerous adverse consequences, including misfolding of the fusion protein, low protein yield, or impaired biological activity. Therefore, the selection or rational design of linkers that connect fusion protein domains is a crucial area in recombinant fusion protein technology.

[0117] The following factors should be considered when designing a linker: 1) Linker length. It should not be too long or too short, generally ranging from 10 to 15 amino acids. A linker sequence that is too long may reduce the yield of the fusion protein and cause immunogenicity issues. A linker sequence that is too short may place the two proteins too close together, affecting the folding of their higher-order structures, leading to mutual interference and loss of protein function. 2) Linker structure. When designing the linker sequence, care should be taken to avoid the formation of secondary structures, as these can limit the flexibility of the fusion protein and thus affect its functional activity. 3) Common amino acids in the linker. Non-polar, hydrophobic amino acids such as glycine (Gly), serine (Ser), and proline (Pro) are more common. 4) Nucleotide sequence within the linker. Studies have shown that adjusting the nucleotide composition of the linker sequence can significantly increase the mRNA levels of the recombinant fusion protein and improve transfection efficiency.

[0118] nuclear localization signal

[0119] A nuclear localization signal (NLS) is an amino acid sequence that "tags" a protein for import into the cell nucleus via nuclear transport. That is, proteins with an NLS are transported to the cell nucleus. Typically, an NLS comprises a positively charged Lys or Arg residue exposed on the surface of the protein. Exemplary nuclear localization sequences include, but are not limited to, NLSs from the following: SV40 large T antigen, EGL-13, c-Myc, and TUS proteins. In some embodiments, the NLS comprises the PAAKRVKLD sequence (c-Myc NLS, SEQ ID No. 23). In some embodiments, the NLS comprises the KRTADGSEFESPKKKRKV sequence (BP NLS, SEQ ID No. 25). In some embodiments, the NLS comprises the KRPAATKKAGQAKKKK sequence (nucleoplasmin NLS, SEQ ID No. 27).

[0120] c-Myc NLS nucleotide sequence 5'-CCCGCCGCCAAGCGCGTGAAGCTGGAC-3' (SEQ ID No. 22),

[0121] c-Myc NLS amino acid sequence PAAKRVKLD (SEQ ID No. 23),

[0122] BP NLS nucleotide sequence 5'-AAACGGACAGCCGACGGAAGCGAGTTCGAGTCACCAAAGAAGAAGCGGAAGGTC-3' (SEQ ID No. 24),

[0123] BP NLS amino acid sequence KRTADGSEFESPKKKRKV (SEQ ID No. 25),

[0124] Nucleoplasmin NLS nucleotide sequence 5'-AAGAGGCCTGCTGCTACAAAGAAGGCCGGCCAGGCAAAAAAGAAAAAG-3' (SEQ ID No. 26),

[0125] The amino acid sequence of nucleoplasmin NLS is KRPAATKKAGQAKKKK (SEQ ID No. 27).

[0126] carrier

[0127] Refers to a self-replicating DNA molecule that transfers DNA fragments (target genes) to recipient cells in genetic engineering recombinant DNA technology. The three most commonly used vectors are bacterial plasmids, bacteriophages, and animal and plant viruses. Vectors can be divided into cloning vectors and expression vectors according to their function. Cloning vectors are the simplest vectors and are mainly used to clone and amplify DNA fragments. They mainly include plasmid vectors, bacteriophage vectors, and viral vectors. In addition to the basic elements of cloning vectors, expression vectors also have DNA elements necessary for transcription and translation, such as promoters and terminators. The promoters involved in this article include U6 and CBh promoters. The U6 promoter belongs to the pol III type promoter. The sequence length it drives is very small. Currently, gRNA and siRNA are commonly expressed using the U6 promoter. The sequence driven by the U6 promoter will terminate when it encounters pol (U). The CBh promoter is an artificially constructed combination promoter composed of a mixed sequence of the cytomegalovirus (CMV), the early enhancer element, the chicken β-actin promoter, and the chicken β-actin (CBA) and minute virus of mice (MMV) introns. It is used to drive high-level gene expression in mammalian vectors.

[0128] T7E1 digestion

[0129] T7E1, short for T7 Endonuclease I, is a specialized DNA endonuclease that recognizes and cleaves imperfectly paired DNA, cruciform DNA, and Holliday structures. T7E1 is commonly used to detect mutants generated by CRISPR / Cas, TALEN, and other editing tools.

[0130] The primary goat or sheep fibroblasts used in the following examples were isolated in the laboratory. Preparation was as follows: A small amount of ear tissue from a goat or sheep within two weeks of birth was placed in PBS. In a cleanroom, the ear tissue was sterilized in 75% alcohol for 1 minute, washed three times with PBS, and minced into 1 mm pieces using sterile scissors. 3 Size the tissue, add 200 μL of fetal bovine serum, transfer to a cell culture dish, and incubate upside down in a 37°C, 5% CO2 incubator for 1 hour. Carefully add complete culture medium, taking care not to dislodge the tissue. After approximately one week of culture, fibroblasts should emerge from the tissue. Once fully grown, trypsinize the cells, expand the culture, and freeze for later use.

[0131] The amino acid sequence of the Cas12i3 protein in the following examples is positions 1-1045 of SEQ ID No. 9, and the nucleotide sequence of the gene encoding the Cas12i3 protein is positions 1-3135 of SEQ ID No. 10.

[0132] In the following examples, the amino acid sequence of T5 exonuclease (abbreviated as T5 exo) is shown at positions 1056-1346 of SEQ ID No. 9, and the nucleotide sequence of the gene encoding T5 exonuclease is shown at positions 3166-4038 of SEQ ID No. 10.

[0133] The PX458 vector in the following examples is derived from the Addgene plasmid sharing information library (number 48138).

[0134] In the following examples, the amino acid sequence of linker 1 is SEQ ID No. 1, and the nucleotide sequence is SEQ ID No. 5; the amino acid sequence of linker 2 is SEQ ID No. 2, and the nucleotide sequence is SEQ ID No. 6; the amino acid sequence of linker 3 is SEQ ID No. 3, and the nucleotide sequence is SEQ ID No. 7; and the amino acid sequence of linker 4 is SEQ ID No. 4, and the nucleotide sequence is SEQ ID No. 8.

[0135] Example 1: Design of different T5 exonuclease and linker nucleic acid molecule combinations

[0136] The present embodiment designs different T5 exonucleases and linker nucleic acid molecule combinations for constructing fusion genes. Taking into account the size of Cas12i3 protein and T5 exonucleases, the linker selected is 8-16 amino acids. Designed 4 kinds of linkers, namely (GGGGS) 2 (amino acid sequence is SEQ ID No.1), (GGGGS) 3 (amino acid sequence is SEQ ID No.2), SGGSGGSGGS (amino acid sequence is SEQ ID No.3), XTEN (amino acid sequence is SEQ ID No.4) and renamed linker 1, linker 2, linker 3, linker 4. And T5 exonucleases are fused to the N-terminal or C-terminal of Cas12i3 protein by these 4 kinds of linkers, a total of 8 kinds of nucleic acid molecule combinations, and 8 kinds of fusion genes are designed. The coding genes of Cas12i3 protein, T5 exonucleases and 4 kinds of linkers have been optimized by mammalian codons. To enhance the nuclear import of the fusion proteins, nuclear localization signal (NLS) sequences were added to the N- and C-termini of the eight fusion genes in this example. The c-Myc NLS and BP NLS coding sequences were added to the N-terminus, and the nucleoplasmin NLS coding sequence was added to the C-terminus.

[0137] According to the above ideas, 8 recombinant vectors were constructed, as shown in Table 1:

[0138] Table 1. Combinations of 8 nucleic acid molecules and vector construction

[0139] The construction methods of the above 8 recombinant vectors are as follows:

[0140] 1. Synthesis of 8 fusion genes

[0141] 8 kinds of fusion genes are fusion genes formed by directly connecting the coding gene of Cas12i3 protein (nucleotide sequence is position 1-3135 of SEQ ID No.10) and the coding gene of T5 exonuclease (T5 exo) (nucleotide sequence is position 3166-4038 of SEQ ID No.10) through the coding gene of linker 1 (nucleotide sequence is SEQ ID No.5), the coding gene of linker 2 (nucleotide sequence is SEQ ID No.6), the coding gene of linker 3 (nucleotide sequence is SEQ ID No.7) or the coding gene of linker 4 (nucleotide sequence is SEQ ID No.8) according to 8 combinations (Table 1).

[0142] The fusion genes synthesized according to the combination of N-linker 1 to N-linker 4 were named T5 exo-linker 1-Cas12i3, T5 exo-linker 2-Cas12i3, T5 exo-linker 3-Cas12i3, and T5 exo-linker 4-Cas12i3, respectively; the fusion genes synthesized according to the combination of C-linker 1 to C-linker 4 were named Cas12i3-linker 1-T5 exo, Cas12i3-linker 2-T5 exo, Cas12i3-linker 3-T5 exo, and Cas12i3-linker 4-T5 exo, respectively.

[0143] 2. Construction of 8 recombinant vectors

[0144] PX458 (U6-sgRNA-CBh-Cas9-T2A-EGFP-bGH polyA) was double-digested with the restriction endonucleases BbsI (NEB (Beijing) Co., Ltd.) and XbaI (NEB (Beijing) Co., Ltd.) to remove the sgRNA scaffold sequence. The digestion system consisted of 5 μg of PX458, 25 units of BbsI, 25 units of XbaI, 10 μL of cutsmart, and ddH2O to 100 μL. Reaction conditions: Incubation at 37°C for 6 hours. The DNA was recovered using a recovery kit (Guangzhou Meiji Biotechnology Co., Ltd., Cat. No. D2111-02) and the concentration was determined. The synthetic primers 5'-CACCACTAGTT-3' (SEQ ID No. 28) and 5'-CTAGAACTAGT-3' (SEQ ID No. 29) were annealed to generate a double-stranded DNA complementary to the linearized PX458 vector after digestion. Annealing system: 2.5 μL of 5'-CACCACTAGTT-3' (100 μM), 2.5 μL of 5'-CTAGAACTAGT-3' (100 μM), 1 μL of T4 ligase buffer, and 10 μL of ddH2O. Annealing procedure: Heat in a metal bath at 95°C for 5 min, then open the bath lid, close the bath, and allow to cool to room temperature. The recovered linearized PX458 vector (double-digested with BbsI and XbaI) and the annealed product were ligated using a T4 ligase kit (Baori Biotechnology Co., Ltd.) to form the U6-CBh-Cas9-T2A-EGFP-bGH polyA.

[0145] The Cas9 coding sequence was removed by double digestion of the plasmid U6-CBh-Cas9-T2A-EGFP-bGH polyA with the restriction endonucleases AgeI (NEB (Beijing) Co., Ltd.) and FseI (NEB (Beijing) Co., Ltd.). The digestion system consisted of 5 μg of the plasmid (U6-CBh-Cas9-T2A-EGFP-bGH polyA), 20 units of AgeI, 20 units of FseI, 10 μL of cutsmart, and ddH2O to 100 μL. Reaction conditions: Incubate at 37°C for 6 hours. The fragments were recovered using a recovery kit (Guangzhou Meiji Biotechnology Co., Ltd., Cat. No. D2111-02) and the concentration was determined. The digestion product (AgeI and FseI double-digested plasmid U6-CBh-Cas9-T2A-E GFP-bGH polyA), the coding sequence of Cas12i3 protein (positions 1-3135 of SEQ ID No. 10), c-Myc NLS, BP NLS and nucleoplasmin NLS were assembled using a seamless cloning kit to obtain U6-CBh-c-Myc NLS-BP NLS-Cas12i3-nucleoplasmin NLS-T2A-EGFP-bGH poly A, which was used as a control vector.The enzyme digestion products (AgeI and FseI double-digested plasmid U6-CBh-Cas9-T2A-EGFP-bGH polyA) and Cas12i3 protein coding sequence, T5 exo coding sequence, linker (linker 1, linker 2, linker 3 or linker 4), c-Myc NLS, BP NLS and nucleoplasmin NLS were assembled using a seamless cloning kit according to the combination shown in Table 1 to obtain the recombinant vectors U6-CBh-c-Myc NLS-BP NLS-T5 exo-linker 1-Cas12i3-nucleoplasmin NLS-T2A-EGFP-bGH polyA, U6-CBh-c-Myc NLS-BP NLS-T5 exo-linker 2-Cas12i3-nucleoplasmin NLS-T2A-EGFP-bGH polyA, U6-CBh-c-Myc NLS-BP NLS-T5 exo-linker 3-Cas12i3-nucleoplasmin NLS-T2A-EGFP-bGH polyA, U6-CBh-c-Myc NLS-BP NLS-T5 exo-linker 4-Cas12i3-nucleoplasmin NLS-T2A-EGFP-bGH polyA, U6-CBh-c-Myc NLS-BP NLS-Cas12i3-linker 1-T5 exo-nucleoplasmin NLS-T2A-E GFP-bGH polyA, U6-CBh-c-Myc NLS-BP NLS-Cas12i3-linker 2-T5 exo-nucleo plasmin NLS-T2A-EGFP-bGH polyA, U6-CBh-c-Myc NLS-BP NLS-Cas12i3-linker 3-T5 exo-nucleoplasmin NLS-T2A-EGFP-bGH polyA and U6-CBh-c-Myc NLS-BP NLS-Cas12i3-linker 4-T5 exo-nucleoplasmin NLS-T2A-EGFP-bGH polyA.

[0146] The above 8 recombinant vectors express 8 fusion proteins (i.e., fusion proteins encoded by 8 fusion genes), which are respectively named: T5 exo-(GGGGS)2-Cas12i3, T5 exo-(GGGGS)3-Cas12i3, T5 exo-SGGSGGSGGS-Cas12i3, T5 exo-XTEN-Cas12i3, Cas12i3-(GGGGS)2-T5 exo, Cas12i3-(GGGGS)3-T5 exo, Cas12i3-SGGSGGSGGS-T5 exo, and Cas12i3-XTEN-T5 exo.

[0147] Example 2: T7E1 enzyme digestion method to detect the editing efficiency of nucleic acid molecules with different T5 exonuclease and linker combinations

[0148] 1. Construction of gene editing vector

[0149] The 8 recombinant vectors and control vectors constructed in Example 1 were double-enzymed by KpnI (NEB (Beijing) Co., Ltd.) and SpeI (NEB (Beijing) Co., Ltd.) and recovered (there are SpeI and KpnI enzyme recognition sites after the U6 promoter). Enzyme digestion system: 5 μg of the above-mentioned plasmid, 50 units of SpeI, 50 units of KpnI, 10 μL of cutsmart, and ddH2O supplemented to 100 μL. Reaction conditions: incubate at 37°C for 6 hours. Then, 5 μL of BeyoAP alkaline phosphatase (Biyuntian Biotechnology Co., Ltd., product number D7027) was added and incubated at 37°C for another 10 minutes. The concentration was recovered and detected using a recovery kit (Guangzhou Meiji Biotechnology Co., Ltd., product number D2111-02).

[0150] The present invention selects the sheep endogenous gene ZFX (GenBank Accession No. NC_056080.1, positions 22500545-22537460 (Update Date 4-Nov-2022)) and designs the target sequence of the gRNA (gRNA1) targeting the ZFX gene. The target sequence is 5'-CAGTACAGCAAGAGTGGATGAAT-3' (SEQ ID No. 15). The DNA fragment expressing gRNA (5'-aaaggacgaaacaccGCTCTGACCACCTGAGAGAATGTGTGCATAGTCACACCAGTACAGCAAGAGTGGATGAATTTTTTTTgtacccgttacataa-3', SEQ ID No. 30, wherein the capital letters indicate the direct repeat sequence + target sequence + transcription termination signal, and the lowercase letters indicate the vector homologous sequence) was amplified by the following primers (Table 2). PCR amplification system: F 1 μL, R 1 μL, PrimeSTAR 15 μL, ddH2O 13 μL. PCR amplification program: 98°C pre-denaturation for 3 min; 98°C denaturation for 10 s, 60°C annealing for 15 s, 72°C extension for 5 s (33 cycles); 72°C extension for 5 min. After PCR completion, PCR products were recovered using a product recovery kit (Guangzhou Meiji Biotechnology Co., Ltd., Cat. No. D2111-02) and their concentrations were determined.

[0151] Table 2. Primers used to amplify DNA fragments expressing gRNA (targeting the ZFX gene)

[0152] The above gRNA fragments were homologously recombined with the linear control vector and 8 recombinant vectors after double digestion with SpeI and KpnI using a seamless cloning kit to form a control vector with ZFX target and 8 recombinant vectors, which are gene editing vectors.

[0153] The eight gene editing vectors constructed above were named pCBh-N-linker 1-gRNA1, pCBh-N-linker 2-gRNA1, pCBh-N-linker 3-gRNA1, pCBh-N-linker 4-gRNA1, pCBh-C-linker 1-gRNA1, pCBh-C-linker 2-gRNA1, pCBh-C-linker 3-gRNA1, and pCBh-C-linker 4-gRNA1, respectively.

[0154] The above-mentioned gene editing vector contains the ZFX gene editing target and the fusion gene designed by the present invention (including the coding gene of the Cas12i3 protein, the coding gene of the T5 nuclease, and the linker gene designed by the present invention). After being introduced into the recipient cell, the guide RNA transcribed therefrom can target the ZFX gene through base complementary pairing, and the fusion protein expressed therefrom (a fusion protein formed by connecting the Cas12i3 protein and the T5 nuclease through a linker) causes double-strand breaks in the DNA upstream and downstream of the ZFX gene target, and after the break, T5 exo can remove the protruding overhang, thereby preventing the cell from accurately repairing, increasing the insertion and deletion ratio, and further realizing the gene editing function.

[0155] 2. Cell electrofection

[0156] Primary sheep fibroblasts in good condition were transferred to a 10 cm culture dish and cultured until the cell confluence was about 80%. The cells were collected by trypsin digestion and transferred to an EP tube. Suspended with 100 μL electroporation solution (Beijing Ingen Biotechnology Co., Ltd., catalog number 98668-20) and added with 7 μg of plasmid (gene editing vector) and mixed evenly. Placed in a Lonza Amaxa Nucleofector 2B cell nuclear transfection instrument, adjusted to program A-033, and electroporated. After electroporation, 500 μL of DMEM high glucose medium was immediately added and allowed to stand in a cell culture incubator at 37°C for 10 minutes. The cells were plated into a 6-well plate with complete culture medium containing 20% ​​FBS. After 6 hours, the culture medium was changed to complete culture medium containing 15% FBS.

[0157] 3. T7E1 detection editing efficiency

[0158] After 48 hours of electroporation, the cells were used to extract the genome using a genome extraction kit (Guangzhou Meiji Biotechnology Co., Ltd., catalog number D3018-02). 100 ng of the extracted sheep genome was used as a template for PCR amplification. Amplification reaction system and amplification procedure: The total volume of the amplification reaction was 50 μL, and the primers in Table 3 were used for amplification. The various components were: 100 ng DNA template, 1 μL of each 10 μmol / L primer, 25 μL of PrimeSTAR (Baori Medical Biological Technology Co., Ltd.), and the volume was filled to 50 μL with sterile deionized water. The PCR reaction procedure was: pre-denaturation at 98°C for 3 minutes; denaturation at 98°C for 10 seconds, annealing at 60°C for 15 seconds, and extension at 72°C for 30 seconds (33 cycles); and finally extension at 72°C for 5 minutes. After PCR was completed, the PCR product was recovered using a product recovery kit and the concentration was determined.

[0159] Table 3. Primers for obtaining sequences around the target site

[0160] Prepare the enzyme digestion system as follows: 500 ng of amplified product, 1.1 μL of cutsmart buffer, and 11.5 μL of ddH2O. Mix thoroughly and follow the hybridization protocol: 95°C for 10 min; ramp down to 85°C at -2°C / s; ramp down to 25°C at -0.1°C / s. Add 0.5 μL of T7E1 (NEB (Beijing) Co., Ltd.) and digest at 37°C for 15 min. Immediately add 2 μL of loading buffer and prepare a 2% agarose gel for electrophoresis analysis. Analyze the digestion results using a gel imaging system.

[0161] It was observed by agarose gel electrophoresis (Figure 1) that the editing efficiency of the fusion protein T5 exo-XTEN-Cas12i3 (N-linker 4 combination, amino acid sequence is SEQ ID No.11) was 15.5%, which was 32.5% higher than the editing efficiency of the unmodified Cas12i3 protein; the editing efficiency of the fusion protein Cas12i3-(GGGGS)2-T5 exo (C-linker 1 combination, amino acid sequence is SEQ ID No.13) was 15.9%, which was 35.9% higher than the editing efficiency of the unmodified Cas12i3 protein; the editing efficiency of the fusion protein Cas12i3-SGGSGGSGGS-T5 exo (C-linker 3 combination, amino acid sequence is SEQ ID No.9) was 15.9%, which was 35.9% higher than the editing efficiency of the unmodified Cas12i3 protein; compared with 11.7% of the control group (unmodified Cas12i3 protein), the editing efficiency was greatly improved.

[0162] Example 3: Flow cytometry analysis to detect the editing efficiency of different combinations of T5 exonuclease and linker nucleic acid molecules

[0163] 1. Construction of tdTomato red fluorescent labeled sheep fibroblasts

[0164] 1-1. Construction of CRISPR / Cas9 gene targeting vector

[0165] 1-1-1. Enzyme digestion of PX458 vector

[0166] Enzyme digestion system: 5 μg of PX458 vector, 50 units of BbsI, 10 μL of cutsmart, and ddH2O to 100 μL. Digestion was carried out at 37°C for 5 h. After digestion, the digestion product was purified using a product purification kit (Guangzhou Meiji Biotechnology Co., Ltd.) to obtain the purified PX458BbsI digestion product. Target oligos were designed based on the goat ZFY gene sequence and synthesized according to Table 4.

[0167] Table 4. sgRNA target sequences

[0168] 1-1-2. Oligo annealing

[0169] The designed oligos are annealed according to the following annealing system and annealing program to form annealing products (double-stranded DNA).

[0170] Annealing system: ZFY-sgRNA-F (100 μM) 2.5 μL, ZFY-sgRNA-R (100 μM) 2.5 μL, T4 ligase buffer 1 μL, ddH2O to 10 μL. Annealing procedure: Incubate in a metal bath at 95°C for 5 min. Close the metal bath, open the lid, and wait for the bath to cool to room temperature before removing from the heat.

[0171] 1-1-3. Connection

[0172] The annealed product was diluted 50-fold and ligated with the PX458BbsI digested product in step 1-1-1 according to the following ligation system and ligation procedure.

[0173] Ligation system: 90 ng of PX458 BbsI digested product, 1 μL of diluted annealed product, 0.5 μL of T4 ligase, 1 μL of T4 ligase buffer, and ddH2O to 10 μL. Ligation procedure: Incubate at 25°C for 1 hour.

[0174] 10 μL of the ligation product was used for transformation, bacteria were picked for sequencing, and plasmids were extracted to construct a CRISPR / Cas9 gene targeting vector (i.e., sgRNA expression vector) named PX458-ZFY-sgRNA.

[0175] 1-2. Construction of donor plasmid

[0176] Our laboratory maintains the pCBh-tdTomato-SV40 polyA plasmid. The construction process of this plasmid is as follows: first, pROSA26-promoter (Addgene 21710) was double-digested with SpeI and XbaI to obtain the digested pROSA26-promoter. The DNA molecule represented by SEQ ID No. 17 (tdTomato-SV40 polyA sequence) was ligated with the digested pROSA26-promoter using seamless cloning and assembly technology to obtain pROSA26-tdTomato-SV40 polyA. px458 was then double-digested with KpnI and AgeI to obtain the CBh promoter. Using pROSA26-tdTomato-SV40polyA as a template, the sequence other than the ROSA26 promoter was amplified with primers F (5'-tttttttcaggttggaccggTGCCACCATGGACTAGTATGGTGAGCAAGGGCGA-3', SEQ ID No.37) and R (5'-taccgtaagttatgtaacggggtacCCAGCTTTTGTTCCCTTTAGT-3', SEQ ID No.38). This sequence was then combined with the CBh promoter sequence by seamless cloning and assembly technology to construct pCBh-tdTomato-SV40polyA.

[0177] This plasmid can normally express red fluorescence in primary goat fibroblasts. The sequences flanking the nuclease cleavage site of the ZFY target (3-4 bp upstream of the PAM) served as homology arms (the left homology arm (HA-L) is 925 bp with the nucleotide sequence of SEQ ID No. 18, and the right homology arm (HA-R) is 958 bp with the nucleotide sequence of SEQ ID No. 19). The left and right homology arms were amplified by PCR using the primers in Table 5, and the PCR product was recovered using a PCR product recovery kit (Meiji Biotechnology Co., Ltd.).

[0178] The plasmid pCBh-tdTomato-SV40 polyA was digested with enzymes, and the left and right homology arms of the ZFY target were cloned into the opposite ends of pCBh-tdTomato-SV40 polyA using seamless cloning and assembly technology to construct the plasmid HA-L-CBh-tdTomato-SV40 polyA-HA-R. ZFY target recognition sequences were then added to the outer edges of the left and right homology arms to create the donor plasmid required for HMEJ (homology-mediated end joining). Furthermore, although the left and right homology arms on the constructed donor plasmid are derived from goat, they share high homology with the corresponding sites in sheep. NCBI BLAST comparison revealed 96.11% identity for the left homology arm and 97.66% for the right homology arm. The nucleotide sequences of the sheep left homology arm are SEQ ID No. 20, and the nucleotide sequences of the sheep right homology arm are SEQ ID No. 21.

[0179] Table 5. ZFY left and right homology arm primers

[0180] 1-3. Construction of tdTomato red fluorescent labeled sheep fibroblasts

[0181] Using the CRISPR / Cas9 gene targeting vector PX458-ZFY-sgRNA constructed in this example and the donor plasmid HA-L-CBh-tdTomato-SV40polyA-HA-R (carrying the exogenous gene tdTomato gene, although the homology arms are derived from goats, they have high homology with the corresponding homology arms of sheep and are therefore expected to be used in sheep), the exogenous gene (tdTomato gene) is site-specifically integrated into the target site of the ZFY gene through HMEJ-mediated recombination, thereby constructing an ovine fibroblast cell line with site-specific integration of the exogenous gene in the ZFY gene. The specific steps are as follows:

[0182] 1-3-1. Co-transfection of gene editing plasmid and donor plasmid into sheep fibroblasts

[0183] Take the constructed donor plasmid HA-L-CBh-tdTomato-SV40 polyA-HA-R 5000ng and the gene targeting vector PX458 (PX458-ZFY-sgRNA) carrying the ZFY target 9536ng (molar ratio 1:1.5) and electroporate (the electroporation step is the same as the electroporation step in step 2 of Example 2, only the added plasmid is different) to primary sheep fibroblasts. After 24 hours, tdTomato and EGFP-positive primary sheep fibroblasts were sorted by flow cytometry and plated into 10cm cell culture dishes at approximately 500 cells per dish. After culturing for 2 weeks, the cells in the cell culture dishes were monocloned and cultured in 96-well plates using cloning rings.

[0184] 1-3-2. Screening of Sheep Fibroblasts with Site-Specific Integration of tdTomato

[0185] After the 96-well plate is confluent with cell colonies, digest the cells, leaving half of the wells in culture and transferring the other half to a 1.5 mL centrifuge tube. Centrifuge at 12,000 rpm for 3 minutes, discard the supernatant, and add 50 μL of cell identification lysis buffer (cell identification lysis buffer preparation: Tris-HCl (1 M, pH 8.0) 2 mL, Triton X-100 0.45 mL, NP-40 0.45 mL, Proteinase K 0.02 g, dissolve in deionized water and dilute to 50 mL, then filter through a 0.22 μm filter). Thoroughly resuspend the cells and lyse according to the following schedule: 65°C for 30 minutes; 95°C for 15 minutes; 16°C for ∞. The resulting lysate will serve as the DNA template.

[0186] Primers were designed according to Table 6 and PCR identification was performed.

[0187] Table 6. Site-directed integration identification primers

[0188] Amplification Reaction System and Procedure: The total volume of the amplification reaction was 50 μL, consisting of 1 μL of DNA template, 1 μL of each 10 μmol / L primer, and 10 μL of PrimeSTAR (Baori Biotechnology Co., Ltd.). The volume was made up to 20 μL with sterile deionized water. The PCR reaction procedure was as follows: initial denaturation at 98°C for 3 min; 33 cycles of denaturation at 98°C for 10 s, annealing at 62°C for 15 s, and extension at 72°C for 50 s; and a final extension at 72°C for 5 min. After completion of PCR, the results were analyzed by agarose gel electrophoresis.

[0189] The results showed that 16 cell clones were lysed, and three clones were identified by PCR as having site-specific integration of ZFY. Fluorescence microscopy revealed that all three clones emitted red fluorescence, indicating that the exogenous gene (tdTomato gene) had integrated specifically at the target site, successfully constructing tdTomato red fluorescently labeled sheep fibroblasts.

[0190] 2. Design target sequences and construct gene editing vectors

[0191] In this example, the cell clone of the ZFY site-directed integration of tdTomato constructed in step 1 above was selected as the cell line for subsequent evaluation of the editing efficiency of connecting T5 and Cas12i3 by different linkers. In this example, a gRNA (gRNA2) targeting tdTomato was designed for the tdTomato ato coding sequence (GenBank Accession No. KT878736.1, positions 2529-3959 (Update Date 06-OCT-2015)), and the target sequence was 5'-AAGACCATCTACATGGCCAAGAA-3' (SEQ ID No. 16). The DNA fragment expressing the gRNA sequence was amplified by the primers in Table 7 (5'-aaaggacgaaacaccGCTCTGACCACCTGAGAGAATGTGTGCATAGTCACACAAGACCATCTACATGGCCAAGAATTTTTTTgtacccgttacataa-3', SEQ ID No. 47, wherein the capital letters indicate the direct repeat sequence + target sequence + transcription termination signal, and the lowercase letters indicate the vector homologous sequence) and the PCR product was recovered by a product recovery kit (Guangzhou Meiji Biotechnology Co., Ltd., Cat. No. D2111-02) and the concentration was determined.

[0192] Table 7 Primers used to amplify DNA fragments expressing gRNA (targeting tdTomato gene)

[0193] The above gRNA fragments were homologously recombined with the linear control vector and 8 recombinant vectors after double digestion with SpeI and KpnI in Example 2 using a seamless cloning kit to form a control vector with tdTomato target and 8 recombinant vectors, which are gene editing vectors.

[0194] The eight gene editing vectors constructed above were named pCBh-N-linker 1-gRNA2, pCBh-N-linker 2-gRNA2, pCBh-N-linker 3-gRNA2, pCBh-N-linker 4-gRNA2, pCBh-C-linker 1-gRNA2, pCBh-C-linker 2-gRNA2, pCBh-C-linker 3-gRNA2, and pCBh-C-linker 4-gRNA2, respectively.

[0195] The above-mentioned gene editing vector contains the tdTomato gene editing target and the fusion gene designed by the present invention (including the coding gene of the Cas12i3 protein, the coding gene of the T5 nuclease, and the linker gene designed by the present invention). After being introduced into the recipient cell, the guide RNA transcribed therefrom can target the tdTomato gene through base complementary pairing, and the fusion protein expressed therefrom (a fusion protein formed by connecting the Cas12i3 protein and the T5 nuclease through a linker) causes double-strand breaks in the DNA upstream and downstream of the tdTomato gene target, and after the break, T5 exo can remove the protruding overhang, thereby preventing the cell from accurately repairing, increasing the insertion and deletion ratio, and further realizing the gene editing function.

[0196] 3. Flow cytometry analysis of tdTomato fluorescence changes

[0197] The plasmids (gene editing vectors pCBh-N-linker 1-gRNA2, pCBh-N-linker 2-gRNA2, pCBh-N-linker 3-gRNA2, pCBh-N-linker 4-gRNA2, pCBh-C-linker 1-gRNA2, pCBh-C-linker 2-gRNA2, pCBh-C-linker 3-gRNA2, pCBh-C-linker 4-gRNA2) were transfected into the tdTomato red fluorescent labeled sheep fibroblasts constructed in step 1. The electroporation step was the same as that in Example 2. After 48 hours, the effects of the control group and different nucleic acid combinations on the changes in tdTomato red fluorescence intensity of EGFP-positive cells (only EGFP-positive cells were considered because the above-mentioned control vector and the eight gene editing vectors all carried the EGFP expression sequence, which was derived from the PX458 vector. EGFP-positive cells represent cells that were successfully transfected with the plasmid, which helps to reduce the error caused by cell transfection) were analyzed by flow cytometry. Specifically, the proportion of tdTomato average fluorescence intensity quenching and the weak fluorescence intensity (tdTomato fluorescence intensity in EGFP-positive cells was less than 103 ) of the cell population.

[0198] By calculating the quenching ratio of the average fluorescence intensity of tdTomato in EGFP-positive cells, it was shown that the quenching ratio of the average fluorescence intensity of tdTomato was increased after the C-linker 3 combination modification compared with the control group (Figure 2), indicating that the C-linker 3 combination has a higher editing efficiency on the tdTomato gene, causing the inactivation of tdTomato protein function in more cells, and ultimately leading to the weakening or even quenching of the red fluorescence of more cells, reducing the overall cell tdTomato fluorescence intensity, that is, the quenching ratio of the average fluorescence intensity of tdTomato is larger. Similarly, by calculating the weak tdTomato fluorescence intensity in EGFP-positive cells (<10 3 ) showed that compared with the control group, the weak tdTomato fluorescence intensity (<10 3 ) (Figure 3). Flow cytometry analysis also showed that compared with the control group, the tdTomato fluorescence peak of C-linker 3 shifted to the left as a whole (Figure 4), indicating that the C-linker 3 combination has a higher editing efficiency on the tdTomato gene, causing the tdTomato protein function to be inactivated in more cells, ultimately leading to the weakening or even quenching of red fluorescence, resulting in a decrease in the tdTomato fluorescence intensity of the entire cell population.

[0199] The present invention fuses T5 exonuclease to the N-terminus or C-terminus of Cas12i3 protein through four linkers and designs eight nucleic acid molecule combinations. Through T7E1 enzyme digestion experiment and flow cytometry analysis, some nucleic acid combinations (N-linker 4, C-linker 1, C-linker 3), especially connecting T5 to the C-terminus of Cas12i3 (C-linker 3 combination) through SGGSGGSGGS (SEQ ID No. 3), significantly improve the editing efficiency of Cas enzyme, and have good application prospects.

[0200] The fusion protein obtained after transforming the Cas12i3 protein according to the C-linker 3 combination method is Cas12i3-SGGSGGSGGS-T5 exo. The amino acid sequence of the fusion protein Cas12i3-SGGSGGSGGS-T5 exo is SEQ ID No.9, its encoding gene is the Cas12i3-linker 3-T5 exo gene, and the nucleotide sequence of the Cas12i3-linker 3-T5 exo gene is SEQ ID No.10.

[0201] The fusion protein obtained after transforming the Cas12i3 protein according to the N-linker 4 combination method is T5 exo-XTEN-Cas12i3. The amino acid sequence of the fusion protein T5 exo-XTEN-Cas12i3 is SEQ ID No. 11, the encoding gene is the T5 exo-linker 4-Cas12i3 gene, and the nucleotide sequence of the T5 exo-linker 4-Cas12i3 gene is SEQ ID No. 12.

[0202] The fusion protein obtained after transforming the Cas12i3 protein according to the C-linker 1 combination method is Cas12i3-(GGGGS)2-T5 exo. The amino acid sequence of the fusion protein Cas12i3-(GGGGS)2-T5 exo is SEQ ID No.13, its encoding gene is the Cas12i3-linker 1-T5 exo gene, and the nucleotide sequence of the Cas12i3-linker 1-T5 exo gene is SEQ ID No.14.

[0203] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be practiced over a wide range of parameters, concentrations, and conditions without departing from the spirit and scope of the present invention and without unnecessary experimentation. Although specific embodiments have been given herein, it should be understood that further modifications may be made to the present invention. In summary, this application is intended to encompass any variations, uses, or improvements to the present invention, including those made by conventional techniques known in the art that depart from the scope of the present invention. Applications of the essential features may be made within the scope of the following claims. Industrial Applicability

[0204] The present invention obtains a combination of T5 nuclease and linker coding sequence nucleic acid molecules (C-linker 3 combination, N-linker 4 combination and C-linker 1 combination) that can significantly improve the editing efficiency of Cas enzyme by screening. The fusion protein obtained by the combination of C-linker 3 combination, N-linker 4 combination and C-linker 1 combination has a greater improvement in editing efficiency than the unmodified Cas12i3 protein, which is increased by 35.9%, 32.5% and 35.9% respectively. The results of further flow cytometry detection of the editing efficiency of different combinations showed that after the C-linker 3 combination modification, the tdTomato average fluorescence intensity quenching ratio was improved, and the weak tdTomato fluorescence intensity (<10 3) in the tdTomato fluorescence peak, the overall tdTomato fluorescence peak shifted to the left (the coordinate axis represents the tdTomato fluorescence intensity from weak to strong from left to right), indicating that the C-linker 3 combination modification significantly improved the editing efficiency of the Cas enzyme. The gene editing system prepared using the fusion protein of the present invention has good gene editing efficiency and good application value and prospects.

Claims

1. A fusion protein, characterized in that The fusion protein is any of the following: A1) a protein whose amino acid sequence is SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13; A2) a protein having 80% or more identity with the protein shown in A1) and having the same function as the protein shown in A1) obtained by substitution and / or deletion and / or addition of amino acid residues of the amino acid sequence shown in SEQ ID No.9, SEQ ID No.11 or SEQ ID No.13; A3) A fusion protein having the same function is obtained by connecting a tag or a signal peptide to the N-terminus and / or C-terminus of A1) or A2).

2. A nucleic acid molecule, characterized in that The nucleic acid molecule is any of the following: B1) a nucleic acid molecule encoding the fusion protein of claim 1; B2) the coding sequence is a DNA molecule shown in SEQ ID No.10, SEQ ID No.12 or SEQ ID No.14; B3) The nucleotide sequence is a DNA molecule shown by SEQ ID No.10, SEQ ID No.12 or SEQ ID No.

14.

3. An expression cassette, characterized in that The expression cassette contains the nucleic acid molecule of claim 2.

4. A recombinant vector, characterized in that: The recombinant vector contains the nucleic acid molecule according to claim 2.

5. A recombinant microorganism, characterized in that The recombinant microorganism contains the nucleic acid molecule according to claim 2.

6. A recombinant host cell, characterized in that The recombinant host cell contains the nucleic acid molecule of claim 2.

7. Any of the following uses of the fusion protein according to claim 1: D1) Application in gene editing; D2) Application in the preparation of gene editing systems; D3) Application in the preparation of gene editing products; D4) Application in improving gene editing efficiency.

8. Any of the following uses of the nucleic acid molecule according to claim 2: D1) Application in gene editing; D2) Application in the preparation of gene editing systems; D3) Application in the preparation of gene editing products; D4) Application in improving gene editing efficiency.

9. Any of the following uses of the expression cassette of claim 3: D1) Application in gene editing; D2) Application in the preparation of gene editing systems; D3) Application in the preparation of gene editing products; D4) Application in improving gene editing efficiency.

10. Any of the following uses of the recombinant vector according to claim 4: D1) Application in gene editing; D2) Application in the preparation of gene editing systems; D3) Application in the preparation of gene editing products; D4) Application in improving gene editing efficiency.

11. Any of the following uses of the recombinant microorganism according to claim 5: D1) Application in gene editing; D2) Application in the preparation of gene editing systems; D3) Application in the preparation of gene editing products; D4) Application in improving gene editing efficiency.

12. Any of the following uses of the recombinant host cell according to claim 6: D1) Application in gene editing; D2) Application in the preparation of gene editing systems; D3) Application in the preparation of gene editing products; D4) Application in improving gene editing efficiency.

13. A gene editing system, characterized in that: The gene editing system includes at least any one of the following: E1) The fusion protein of claim 1; E2) The nucleic acid molecule according to claim 2; E3) The recombinant vector according to claim 4.

14. The gene editing system according to claim 13, characterized in that: The gene editing system also includes gRNA or a gRNA expression vector.

15. Use of the gene editing system according to claim 13 or 14 in gene editing, preparing gene editing products or improving gene editing efficiency.

16. A method for gene editing, characterized in that: The method comprises the step of performing gene editing using the fusion protein of claim 1, the nucleic acid molecule of claim 2, the recombinant vector of claim 4 and / or the gene editing system of claim 13 or 14.

17. A method for improving the efficiency of Cas protein-mediated gene editing, characterized in that: The method comprises any of the following: F1) connecting T5 exonuclease to the C-terminus of the Cas protein through linker 3, wherein linker 3 is a polypeptide having an amino acid sequence of SEQ ID No. 3; F2) connecting T5 exonuclease to the N-terminus of the Cas protein through linker 4, wherein linker 4 is a polypeptide having an amino acid sequence of SEQ ID No. 4; F3) T5 nuclease is connected to the C-terminus of the Cas protein through linker 1, and the linker 1 is a polypeptide with an amino acid sequence of SEQ ID No.

1.

18. The method according to claim 17, characterized in that The method also includes the step of constructing the nucleic acid molecule described in claim 2 and the nucleic acid molecule encoding gRNA into a vector to prepare a gene editing vector.

Citation Information

Patent Citations

  • Method and system for carrying out target nucleic acid detection by using novel Cas enzyme

    CN111690773A

  • Methods for target nucleic acid detection by using nucleic acid analogs

    CN111876469A

  • Novel CRISPR / Cas12f enzymes and systems

    CN113106081A

  • Fusion protein and application thereof in gene editing

    CN116769754A

  • A nuclease and application thereof

    WO2022046669A2

Cited By

  • Kit for improving gene editing efficiency and application thereof

    CN122189095A